A UK Single-Center, Retrospective, Noninterventional Study of Clinical Outcomes and Costs of Two BotulinumtoxinA Treatments for Limb Spasticity
Toxins · 2023
DOI: 10.3390/toxins15090532 ↗Kurz gefasst
Fachartikel in der Zeitschrift Toxins, 2023. Verfasst von Clive Bezzina und 8 weiteren Autor:innen. Beteiligte Einrichtung: North Staffordshire Rehabilitation Centre, Haywood Hospital, Stoke-on-Trent ST6 7AG, UK. Hauptthemen laut MEDLINE: Botulinum Toxins, Type A, Neuromuscular Agents. Die Arbeit nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ipsen.
Abstract (Originalsprache)
Service model changes at the North Staffordshire Rehabilitation Centre (UK) included switching spasticity treatment from onabotulinumtoxinA (onaBoNT-A) to abobotulinumtoxinA (aboBoNT-A). This noninterventional, retrospective, longitudinal study (NCT04396704) describes the clinical and economic outcomes in toxin-naive adults with spasticity who received onaBoNT-A (Cohort 1; 2015–2017) or aboBoNT-A (Cohort 2; 2017–2019). Outcomes included Goal Attainment Scale T (GAS-T) score, treatment satisfaction, quality of life (QoL; EQ-5D visual analog scale [VAS] score), and treatment costs. Adverse events were recorded for Cohort 2. Cohort 1 included 60 patients (mean [standard deviation] dose, 206.0 [98.8] U); Cohort 2 included 54 patients (753.7 [457.3] U). Mean (95% confidence interval) GAS-T scores for Cohorts 1 and 2 were 43.1 (39.3–46.9) and 47.8 (43.7–51.9) at Week 6, and 43.2 and 44.3 at Week 12, respectively. In both cohorts most patients were satisfied with treatment. At Week 12, QoL had not changed in Cohort 1 but had improved in Cohort 2 (EQ-5D VAS, −5). Mean estimated per-patient costs (in 2021) for Cohorts 1 and 2 were £315.56 and £249.25, respectively, at Week 6, and £343.20 and £273.21, respectively, at Week 12. Fifteen non–treatment-related serious adverse events and two deaths were recorded. These data may warrant a larger prospective study powered to compare outcomes of aboBoNT-A and onaBoNT-A.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- North Staffordshire Rehabilitation Centre, Haywood Hospital, Stoke-on-Trent ST6 7AG, UK.
- Ipsen, Slough SL1 3XE, UK.
- Ipsen, 92100 Boulogne-Billancourt, France.
ORCID-Profile: Pascal Maisonobe, Emanuel Engmann, John Whalen
Förderung
- Ipsen
Zitieren
APA
Bezzina, C., Degtiar, V., Danchenko, N., Maisonobe, P., Davis, B., Engmann, E., Guyon, E., Lecanuet, S., & Whalen, J. (2023). A UK Single-Center, Retrospective, Noninterventional Study of Clinical Outcomes and Costs of Two BotulinumtoxinA Treatments for Limb Spasticity. Toxins. https://doi.org/10.3390/toxins15090532
Vancouver
Bezzina C, Degtiar V, Danchenko N, Maisonobe P, Davis B, Engmann E, et al. A UK Single-Center, Retrospective, Noninterventional Study of Clinical Outcomes and Costs of Two BotulinumtoxinA Treatments for Limb Spasticity. Toxins. 2023. doi:10.3390/toxins15090532
BibTeX
@article{Bezzina2023,
author = {Bezzina, Clive and Degtiar, Vadim and Danchenko, Natalya and Maisonobe, Pascal and Davis, Benjamin and Engmann, Emanuel and Guyon, Elodie and Lecanuet, Sophie and Whalen, John},
title = {A UK Single-Center, Retrospective, Noninterventional Study of Clinical Outcomes and Costs of Two BotulinumtoxinA Treatments for Limb Spasticity},
journal = {Toxins},
year = {2023},
doi = {10.3390/toxins15090532}
}
EUVIMED